STDs
The latest information on sexually transmitted diseases — summaries and comments on Chlamydia, gonorrhea, herpes, HIV, HPV, syphilis, and more — drawn from across our primary care and specialty care areas. Sign up now for monthly e-mail alerts on new content.
SUMMARY AND COMMENT
Cutaneous Non–AIDS-Defining Cancers in HIV-Infected Individuals
- July 1, 2009
- Larry M. Baddour, MD
- Infectious Diseases
Such cancers are not associated with immune status or receipt of ART.
- Reviewing:
- Crum-Cianflone N et al. Arch Intern Med 2009 Jun 22; 169:1130
SUMMARY AND COMMENT
Clinical Effectiveness of HBV Vaccination in HIV-Positive Patients
- June 29, 2009
- Helmut Albrecht, MD
- HIV/AIDS
In an observational cohort study that showed a high incidence of hepatitis B virus infection after HIV diagnosis, HBV vaccination was effective only in a subgroup with HBV surface antibody titers 
10 IU/L.
- Reviewing:
- Landrum ML et al. AIDS 2009 May 29
SUMMARY AND COMMENT
Rifampin-Resistant TB During Boosted PI Therapy in HIV Patients
- June 29, 2009
- Carlos del Rio, MD
- HIV/AIDS
In New York City, three HIV patients with tuberculosis developed rifampin resistance after being switched to boosted PI therapy and alternate-day rifabutin.
- Reviewing:
- Jenny-Avital ER and Joseph K. Clin Infect Dis 2009 May 15; 48:1471
SUMMARY AND COMMENT
PEPFAR in Sub-Saharan Africa: Effects on HIV-Related Outcomes
- June 29, 2009
- Salim S. Abdool Karim, MD, PhD
- HIV/AIDS
An analysis of PEPFAR’s effectiveness in 12 African countries reveals a significant decrease in the number of HIV-related deaths, but not in HIV prevalence.
- Reviewing:
- Bendavid E and Bhattacharya J. Ann Intern Med 2009 May 19; 150:688
SUMMARY AND COMMENT
Recycling Enfuvirtide: Possible Clinical Benefit
- June 29, 2009
- Keith Henry, MD
- HIV/AIDS
Salvage therapy that included enfuvirtide appeared to show a survival benefit in a small, uncontrolled, retrospective study of HIV-positive patients who had already experienced virologic failure on an enfuvirtide-containing regimen.
- Reviewing:
- Cossarini F et al. J Acquir Immune Defic Syndr 2009 Jun 1; 51:179
SUMMARY AND COMMENT
ART and Neurocognitive Function
- June 24, 2009
- Richard T. Ellison III, MD
- Infectious Diseases
HIV-infected patients with neurocognitive impairment can show progressive improvement in function for at least 48 weeks after starting ART.
- Reviewing:
- Cysique LA et al. Neurology 2009 May 27
SUMMARY AND COMMENT
HPV Vaccine for Women in Mid-Adulthood
- June 23, 2009
- Bruce Soloway, MD
- General Medicine
Infection and disease were prevented in women between the ages of 24 and 45.
- Reviewing:
- Muñoz N et al. Lancet 2009 Jun 6; 373:1949
SUMMARY AND COMMENT
MRSA Colonization and Infection in HIV-Infected Patients
- June 22, 2009
- Rajesh T. Gandhi, MD
- HIV/AIDS
The increased rate of MRSA colonization in HIV-infected patients probably explains their elevated rate of MRSA skin and soft-tissue infections.
- Reviewing:
- Shet A et al. J Infect Dis 2009 Jul 1; 200:88
SUMMARY AND COMMENT
High Rate of New HIV Infection in Late Pregnancy
- June 8, 2009
- Keith Henry, MD
- HIV/AIDS
Among pregnant women in South Africa, repeat testing conducted between 36 and 40 weeks of gestation revealed new HIV infection in 3%.
- Reviewing:
- Moodley D et al. AIDS 2009 May 18
SUMMARY AND COMMENT
CNS Penetration of ART and Cognitive Performance: An Unexpected Finding
- June 8, 2009
- Jennifer Johnson, MD, and Paul E. Sax, MD
- HIV/AIDS
Increased CNS penetration effectiveness of the ART regimen was associated with poorer neurocognitive outcomes, despite increased rates of CSF viral suppression.
- Reviewing:
- Marra CM et al. AIDS 2009 May 6
